Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

UCB Announces Positive 2-Year Bimzelx® Data

Nov 14, 2024

On 14 November 2024, UCB announced the presentation of new two-year data from phase 3 studies of Bimzelx® (bimekizumab-bkzx) showing sustained improvements in clinical and patient-reported outcomes in adults with active psoriatic arthritis (PsA) and ankylosing spondylitis (AS).  The data demonstrated that, of responders who achieved at least 50% improvement from baseline response criteria for PsA, 75% maintained response to two years.  Of patients who achieved a 40% improvement in response criteria for AS, 85% maintained this response to two years.

This follows FDA approval of 2 mL pre-filled syringe and pre-filled autoinjector presentations in October 2024, each containing 320 mg of Bimzelx®, adding to the already approved 1 ml (160 mg) device presentation.  On 23 September 2024, UCB received FDA approval for three new indications of Bimzelx®, including active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation and active ankylosing spondylitis.